4D Molecular Therapeutics (FDMT) Asset Utilization Ratio (2021 - 2025)
Historic Asset Utilization Ratio for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.0.
- 4D Molecular Therapeutics' Asset Utilization Ratio rose 86266.05% to 0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0, marking a year-over-year increase of 86266.05%. This contributed to the annual value of 0.0 for FY2024, which is 9988.07% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Asset Utilization Ratio is 0.0, which was up 86266.05% from 0.0 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Asset Utilization Ratio peaked at 0.09 during Q2 2021, and registered a low of 0.0 during Q3 2024.
- In the last 5 years, 4D Molecular Therapeutics' Asset Utilization Ratio had a median value of 0.01 in 2022 and averaged 0.03.
- In the last 5 years, 4D Molecular Therapeutics' Asset Utilization Ratio tumbled by 9995.49% in 2024 and then soared by 86266.05% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Asset Utilization Ratio stood at 0.06 in 2021, then tumbled by 80.99% to 0.01 in 2022, then soared by 411.85% to 0.06 in 2023, then plummeted by 99.89% to 0.0 in 2024, then surged by 320.72% to 0.0 in 2025.
- Its Asset Utilization Ratio stands at 0.0 for Q3 2025, versus 0.0 for Q2 2025 and 0.0 for Q1 2025.